STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Drug-Radiation combo aims to tame returning head and neck cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called camonsertib combined with precise, high-dose radiation for people whose head and neck cancer has come back or cannot be surgically removed. The drug blocks enzymes that help cancer cells grow, while the radiation targets tumors direc…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:01 UTC
-
New hope for head and neck cancer patients who Can't take standard chemo
Disease control Not yet recruitingThis study tests two different treatments for people with advanced head and neck cancer who cannot receive the standard drug cisplatin. Participants will get radiation therapy along with either cetuximab (a targeted antibody) or a combination of two chemotherapy drugs, carboplati…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 26, 2026 08:58 UTC